New combo therapy gives hope to elderly esophageal cancer patients
NCT ID NCT07038629
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the immunotherapy drug iparomlimab after standard chemoradiation can help older adults (70+) with inoperable esophageal cancer live longer without the disease getting worse. About 52 participants will receive the drug for one year after chemoradiation. The goal is to improve outcomes while keeping side effects manageable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Cancer Hospital
RECRUITINGTianjin, Tianjin Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Blood test score may flag High-Risk esophageal surgery patients
- Can surgery for stomach or esophageal cancer cloud the mind?
- Virtual patients could revolutionize cancer drug testing
- Can a pill restore the Body's tumor suppressor to fight multiple cancers?